Most Read Articles
Rachel Soon, 26 Jun 2018

MIMS Pharmacist presents an overview of phosphatidylcholine's physiological role, as well as contemporary research on its pharmacology and effects.

17 Mar 2018
Nonvitamin K antagonist oral anticoagulants (NOAC)-associated intracerebral haemorrhage (ICH) and vitamin K antagonists-ICH appear to have similar ICH volume, haematoma expansion, functional outcome and mortality, results of a recent meta-analysis have shown.
31 May 2017
New drug applications approved by US FDA as of 16 - 31 May 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
09 Dec 2017
Intravenous (IV) iron is less toxic and more effective compared to oral iron, making it a potential frontline therapy for neonatal iron deficiency anaemia, suggests a recent study.

Exenatide improves glycaemic control, weight loss in uncontrolled T2D

Roshini Claire Anthony
26 Sep 2017

Once-weekly doses of the glucagon-like peptide-1 receptor agonist exenatide plus insulin glargine improved glucose control and weight loss in patients whose type 2 diabetes (T2D) was uncontrolled on basal insulin and metformin, according to findings from the DURATION-7* trial.

“Patients receiving exenatide QW were twice as likely to have improved HbA1c and body weight than those treated with titrated insulin glargine alone,” said Dr Juan Pablo Frias from the National Research Institute, Los Angeles, California, US, who presented the findings at EASD 2017.

Patients recruited at screening (n=808) were individuals with uncontrolled T2D (HbA1c ≥7.5 to ≤12.0 percent; mean HbA1c 9.2 percent) on insulin glargine (≥20 U/day) with or without metformin and a sulphonylurea. Following an 8-week run-in period during which insulin glargine was titrated, 464 patients with HbA1c ≥7.0 to ≤10.5 percent (mean HbA1c, 8.5 percent) despite basal insulin and stable metformin (sulphonylurea use was discontinued) were randomized to receive exenatide QW (n=233, mean age 57.8 years, 49.4 percent male, mean baseline weight 93.3 kg) or placebo (n=231, mean age 57.6 years, 46.5 percent male, mean baseline weight 97.4 kg) in addition to titrated insulin glargine (mean, 50 and 52 U/day in the exenatide and placebo groups, respectively) for 28 weeks.

At week 28, about 25 percent more patients on exenatide reached the target glycaemic goal of HbA1c <7.0 percent compared with patients on placebo (p<0.001), with a more evident reduction in HbA1c in patients on exenatide vs placebo (-1.0 percent vs -0.3 percent; least squares [LS] mean change from baseline, -0.7 percent; p<0.001). Patients on exenatide also experienced a mean 1.1 kg weight loss at 28 weeks compared with patients on placebo who gained a mean 0.4 kg (LS mean change, -1.5 kg; p<0.001). [EASD 2017, abstract OP 01(3)]

Almost 20 percent (19.5 percent) more patients on exenatide than placebo achieved the composite of reaching glycaemic targets with no weight gain or incidence of major hypoglycaemia (p<0.001).

A greater proportion of patients on exenatide compared with placebo experienced HbA1c reductions of any amount (80.9 percent vs 59.7 percent) as well as any weight loss (62.3 percent vs 39.8 percent).

Adverse event (AE) and serious AE incidence was comparable between patients on exenatide and placebo (53.9 percent vs 57.6 percent and 4.7 percent vs 4.8 percent, respectively), while more patients on exenatide reported gastrointestinal events (15.1 percent vs 10.8 percent) and injection site-related AEs (7.8 percent vs 3.0 percent).

Hypoglycaemia incidence was comparable between patients on exenatide and placebo (29.7 percent vs 29.0 percent) and there was no incidence of severe hypoglycaemia in either group.

“Clinical benefits of combining exenatide QW with basal insulin included a reduction in HbA1c, with a greater percentage of patients achieving glycaemic targets, reduced body weight, and no increase in hypoglycaemia incidence or rate despite improved glycaemic control,” concluded Frias.

Dr Juan Pablo Frias

Dr Juan Pablo Frias

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 26 Jun 2018

MIMS Pharmacist presents an overview of phosphatidylcholine's physiological role, as well as contemporary research on its pharmacology and effects.

17 Mar 2018
Nonvitamin K antagonist oral anticoagulants (NOAC)-associated intracerebral haemorrhage (ICH) and vitamin K antagonists-ICH appear to have similar ICH volume, haematoma expansion, functional outcome and mortality, results of a recent meta-analysis have shown.
31 May 2017
New drug applications approved by US FDA as of 16 - 31 May 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
09 Dec 2017
Intravenous (IV) iron is less toxic and more effective compared to oral iron, making it a potential frontline therapy for neonatal iron deficiency anaemia, suggests a recent study.